AMPICILLIN\SULBACTAM: 1,655 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
1,655
Total FAERS Reports
308 (18.6%)
Deaths Reported
791
Hospitalizations
1,655
As Primary/Secondary Suspect
224
Life-Threatening
25
Disabilities
Active Ingredient: AMPICILLIN SODIUM\SULBACTAM SODIUM ·
First Report: 1978 · Latest Report: 20250811
What Are the Most Common AMPICILLIN\SULBACTAM Side Effects?
#1 Most Reported
Drug ineffective
258 reports (15.6%)
#2 Most Reported
Off label use
124 reports (7.5%)
#3 Most Reported
Rash
98 reports (5.9%)
All AMPICILLIN\SULBACTAM Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Drug ineffective | 258 | 15.6% | 87 | 145 |
| Off label use | 124 | 7.5% | 35 | 61 |
| Pyrexia | 98 | 5.9% | 8 | 70 |
| Rash | 98 | 5.9% | 2 | 47 |
| Diarrhoea | 93 | 5.6% | 7 | 56 |
| Condition aggravated | 83 | 5.0% | 33 | 59 |
| Drug hypersensitivity | 70 | 4.2% | 2 | 19 |
| Pneumonia | 68 | 4.1% | 24 | 41 |
| Acute kidney injury | 66 | 4.0% | 9 | 34 |
| Drug eruption | 66 | 4.0% | 3 | 38 |
| Pruritus | 54 | 3.3% | 1 | 26 |
| Renal impairment | 54 | 3.3% | 11 | 39 |
| Maternal exposure during pregnancy | 46 | 2.8% | 2 | 21 |
| Erythema | 44 | 2.7% | 1 | 29 |
| Sepsis | 43 | 2.6% | 27 | 34 |
| Drug ineffective for unapproved indication | 40 | 2.4% | 10 | 17 |
| Dyspnoea | 40 | 2.4% | 3 | 25 |
| Hypotension | 40 | 2.4% | 4 | 24 |
| Foetal exposure during pregnancy | 39 | 2.4% | 9 | 2 |
| Toxic epidermal necrolysis | 38 | 2.3% | 15 | 22 |
Who Reports AMPICILLIN\SULBACTAM Side Effects? Age & Gender Data
Gender: 45.5% female, 54.5% male. Average age: 55.5 years. Most reports from: JP. View detailed demographics →
Is AMPICILLIN\SULBACTAM Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 1 | 1 |
| 2006 | 1 | 0 | 0 |
| 2007 | 3 | 1 | 2 |
| 2009 | 3 | 0 | 1 |
| 2010 | 5 | 0 | 5 |
| 2011 | 7 | 3 | 3 |
| 2012 | 7 | 0 | 4 |
| 2013 | 20 | 12 | 10 |
| 2014 | 33 | 2 | 19 |
| 2015 | 47 | 3 | 29 |
| 2016 | 77 | 25 | 46 |
| 2017 | 87 | 20 | 50 |
| 2018 | 74 | 12 | 43 |
| 2019 | 39 | 12 | 18 |
| 2020 | 43 | 1 | 25 |
| 2021 | 32 | 4 | 10 |
| 2022 | 26 | 9 | 13 |
| 2023 | 52 | 3 | 27 |
| 2024 | 35 | 2 | 15 |
| 2025 | 15 | 5 | 7 |
What Is AMPICILLIN\SULBACTAM Used For?
| Indication | Reports |
|---|---|
| Pneumonia | 225 |
| Product used for unknown indication | 183 |
| Antibiotic therapy | 80 |
| Pneumonia aspiration | 63 |
| Infection | 49 |
| Bacterial infection | 41 |
| Cellulitis | 40 |
| Osteomyelitis | 37 |
| Antibiotic prophylaxis | 30 |
| Staphylococcal infection | 30 |
AMPICILLIN\SULBACTAM vs Alternatives: Which Is Safer?
AMPICILLIN\SULBACTAM vs AMPRENAVIR
AMPICILLIN\SULBACTAM vs AMPYRA
AMPICILLIN\SULBACTAM vs AMRUBICIN
AMPICILLIN\SULBACTAM vs AMSACRINE
AMPICILLIN\SULBACTAM vs ANAGRELIDE
AMPICILLIN\SULBACTAM vs ANAKINRA
AMPICILLIN\SULBACTAM vs ANAMORELIN
AMPICILLIN\SULBACTAM vs ANASTROZOLE
AMPICILLIN\SULBACTAM vs ANDEXANET ALFA
AMPICILLIN\SULBACTAM vs ANDROGEL
Official FDA Label for AMPICILLIN\SULBACTAM
Official prescribing information from the FDA-approved drug label.